Relativity Space

Relativity Space is an aerospace company building 3D printing metal and autonomous technologies to build rockets and other space vehicles.

Headquarters

Year Founded

Search Tags

3D-printed rockets, Reusable launch vehicles, Additive manufacturing aerospace

About Us

Relativity Space designs and manufactures reusable rockets using 3D printing technology. The company has successfully launched the world’s first 3D-printed rocket, Terran 1, and is developing a larger vehicle called Terran R. Their innovative approach allows for rapid iteration, reduced part count, and cost-effective production. Relativity Space offers launch services for satellites and other payloads, focusing on meeting the growing demand for space infrastructure. By leveraging additive manufacturing and artificial intelligence, they are revolutionizing the rocket manufacturing process, aiming to reduce complexity and time to market while increasing performance and reliability.

Trending Companies

Latest Articles

Engineer intelligent, AI-driven supply chain operations. Discover what next-generation leaders must master to design resilient, data-driven, high-performing global networks.

The Future of Supply Chain Leadership: Why the Next Generation Will Engineer Intelligence, Not Just Manage It

Supply chain leadership is being redefined by AI, intelligent automation, and agentic decision-making, demanding leaders who can engineer end-to-end intelligence rather than simply manage workflows. This article explores how next-generation supply chain leaders will combine data, algorithms, and human judgment to build resilient, adaptive, and high-performing global operations.

Read More >
Medicare will pilot AI-driven prior authorization in 2026 across six states, targeting high-risk services while clinicians make final decisions.

AI-Powered Prior Authorization Comes to Traditional Medicare

Traditional Medicare will pilot AI-assisted prior authorization in 2026 across six states, focusing on high-risk outpatient services. Clinicians retain final say, but incentives and access concerns loom as CMS tests fraud reduction and “gold card” exemptions. Here’s what providers and patients should know.

Read More >